ForPatients

by Roche

Rheumatoid Arthritis

A Comparative Study to Observe the Effect of Concomitant Use of Corticosteroid Treatment in Rheumatoid Arthritis (RA) Participants Who Are Treated With a Tumor Necrosis Factor (TNF) Inhibitor or Tocilizumab (TCZ) as Their Second Biological Treatment.

Trial Status	Trial Runs In	Trial Identifier
Completed	1 Countries	NCT02679001 ML29933

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This six months non-interventional, observational, post-marketing, multi-center and local study will evaluate the differences in the use of corticosteroids between RA participants receiving TCZ or a TNF-inhibitor, in participants who have discontinued the use of a TNF-inhibitor as their first biological treatment.

Hoffmann-La Roche Sponsor		Phase	
NCT02679001 ML29933 Trial Identifiers			
Eligibility Criteria:			
Gender All	Age >= 18 Years		Healthy Volunteers No